Table 3.

Summary of Infusion Site Reactions in Patients Without a Central Venous Access Device Among the As‐Treated Population

Patients With AEs at the Infusion Site	AEsa			Treatment‐Related AEsa
	Placebo N = 193	Fosnetupitant at a Dose of 81 mg N = 194	Fosnetupitant at a Dose of 235 mg N = 191	Placebo N = 193	Fosnetupitant at a Dose of 81 mg N = 194	Fosnetupitant at Dose of 235 mg N = 191
Total ISRs	11 (5.7)	21 (10.8)	15 (7.9)	0 (0.0)	1 (0.5)	2 (1.0)
Injection site pain	8 (4.1)	14 (7.2)	11 (5.8)	0 (0.0)	0 (0.0)	0 (0.0)
Injection site erythema	5 (2.6)	3 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Injection site induration	3 (1.6)	2 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Injection site thrombophlebitis	0 (0.0)	3 (1.5)	3 (1.6)	0 (0.0)	1 (0.5)	1 (0.5)
Injection site reaction	0 (0.0)	2 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Injection site discomfort	0 (0.0)	0 (0.0)	1 (0.5)	0 (0.0)	0 (0.0)	1 (0.5)

Abbreviations: AE, adverse event; ISR, infusion site reaction.

Data are shown as the number of patients (%).

^aAssessed using National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).